120 related articles for article (PubMed ID: 37578814)
1. Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatment.
Zhou Q; Wu H; Miao F; Cao Y; Liang L; Huang J; Qian Z
Anticancer Drugs; 2023 Oct; 34(9):1046-1057. PubMed ID: 37578814
[TBL] [Abstract][Full Text] [Related]
2.
Li Q; Damish AW; Frazier Z; Liu D; Reznichenko E; Kamburov A; Bell A; Zhao H; Jordan EJ; Gao SP; Ma J; Abbosh PH; Bellmunt J; Plimack ER; Lazaro JB; Solit DB; Bajorin D; Rosenberg JE; D'Andrea AD; Riaz N; Van Allen EM; Iyer G; Mouw KW
Clin Cancer Res; 2019 Feb; 25(3):977-988. PubMed ID: 29980530
[TBL] [Abstract][Full Text] [Related]
3. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
4. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Van Allen EM; Mouw KW; Kim P; Iyer G; Wagle N; Al-Ahmadie H; Zhu C; Ostrovnaya I; Kryukov GV; O'Connor KW; Sfakianos J; Garcia-Grossman I; Kim J; Guancial EA; Bambury R; Bahl S; Gupta N; Farlow D; Qu A; Signoretti S; Barletta JA; Reuter V; Boehm J; Lawrence M; Getz G; Kantoff P; Bochner BH; Choueiri TK; Bajorin DF; Solit DB; Gabriel S; D'Andrea A; Garraway LA; Rosenberg JE
Cancer Discov; 2014 Oct; 4(10):1140-53. PubMed ID: 25096233
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity.
Moisan F; Laroche-Clary A; Auzanneau C; Ricard N; Pourquier P; Robert J; Le Morvan V
Carcinogenesis; 2012 May; 33(5):962-8. PubMed ID: 22345163
[TBL] [Abstract][Full Text] [Related]
6. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
7. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
Börcsök J; Sztupinszki Z; Bekele R; Gao SP; Diossy M; Samant AS; Dillon KM; Tisza V; Spisák S; Rusz O; Csabai I; Pappot H; Frazier ZJ; Konieczkowski DJ; Liu D; Vasani N; Rodrigues JA; Solit DB; Hoffman-Censits JH; Plimack ER; Rosenberg JE; Lazaro JB; Taplin ME; Iyer G; Brunak S; Lozsa R; Van Allen EM; Szüts D; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Apr; 27(7):2011-2022. PubMed ID: 33208343
[TBL] [Abstract][Full Text] [Related]
9. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
10. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.
Gangawar R; Ahirwar D; Mandhani A; Mittal RD
Med Oncol; 2010 Jun; 27(2):159-66. PubMed ID: 19242824
[TBL] [Abstract][Full Text] [Related]
11. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT
Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965
[TBL] [Abstract][Full Text] [Related]
12. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin.
Zhu H; Yun F; Shi X; Wang D
Int J Mol Med; 2015 Aug; 36(2):595-601. PubMed ID: 26080829
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
[TBL] [Abstract][Full Text] [Related]
16. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
17. ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.
Zhang G; Guan Y; Zhao Y; van der Straaten T; Xiao S; Xue P; Zhu G; Liu Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Chem Biol Interact; 2017 Feb; 263():55-65. PubMed ID: 28027876
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
19. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy.
Li H; Yu G; Shi R; Lang B; Chen X; Xia D; Xiao H; Guo X; Guan W; Ye Z; Xiao W; Xu H
Mol Cancer; 2014 Jan; 13():8. PubMed ID: 24423412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
